Koen Hoffman

Chief Executive Officer at Value Square NV

Koen Hoffman

Koen Hoffman

Chief Executive Officer at Value Square NV

Overview
Career Highlights

Value Square NV

RelSci Relationships

330

Number of Boards

7

Birthday

1968

Age

51

Contact Data
Trying to get in touch with Koen Hoffman? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Koen Hoffman likely has professional access to. A relationship does not necessarily indicate a personal connection.

Chief Executive Officer, Chief Business Development Officer & Executive Director at Mithra Pharmaceuticals SA

Relationship likelihood: Strong

Executive Director at Mithra Pharmaceuticals SA

Relationship likelihood: Strong

General Counsel at Alychlo NV

Relationship likelihood: Strong

Chief Financial Officer & Executive Director at Fagron NV

Relationship likelihood: Strong

Founder at Greenyard NV

Relationship likelihood: Strong

Chief Executive Officer at Greenyard NV

Relationship likelihood: Strong

Co-Founder at Omega Pharma NV

Relationship likelihood: Strong

Former Chairman & Non-Executive Member at ING Belgium SA

Relationship likelihood: Strong

Co-Managing Director at Greenyard Fresh Holding DE GmbH & Co. KG

Relationship likelihood: Strong

Former Secretary at Mithra Pharmaceuticals SA

Relationship likelihood: Strong

Paths to Koen Hoffman
Potential Connections via
Relationship Science
You
Koen Hoffman
Chief Executive Officer at Value Square NV
Education
MBA
Class of 1991

Vlerick Leuven Gent Management School is a school in Leuven.

Class of 1990

University of Ghent is a educational institute for training and research under natural and social sciences.

Career History
Chief Executive Officer
2016 - Current

Value Square is an active, value-based manager which performs in-house fundamental analysis to make investments, aiming to achieve the highest possible absolute returns. They do not attach themselves to a reference index, but seek out the best investment ideas. The Asset Management Team analyzes shares or bonds and calculates their intrinsic value in a conservative manner, purchasing only if the upward potential is significant enough.The firm invests in analysis and research, believing that the fundamental value approach offers the best risk-return ratio over the medium- to long-term. They follow a bottom-up approach to primarily invest in shares of listed companies across geographies. If they estimate that the downward risks are higher than the potential return, the portion invested in shares can be reduced in favor of investments in liquidities and money-market instruments. If they feel that the market risk is high, up to 50% of the sub-fund can be invested in liquidities and/or money-market instruments. At least 50% of the sub-fund is always invested in shares.

Professional
Tenure Unconfirmed

Mithra Pharmaceuticals SA engages in the development, manufacture, and commercialization of proprietary and differentiated drugs and generic products dedicated to female healthcare. It specializes in the following domains of health for women: contraception and fertility, menopause and osteoporosis, gynecological infections, and cancers. The company was founded by Jean-Michel Foidart and François Fornieri on July 8, 1999 and is headquartered in Liège, Belgium.

Head of Institutional Sales
1992 - 2016

KBC Securities NV (KBC-S) is the wholly-owned securities specialist subsidiary of KBC Bank, itself a subsidiary of KBC Groupe SA (XB: KBC) in Belgium.Established in 1989, the firm is based in Brussels and has subsidiaries in Hungary, France, Czech Republic and Poland as well as group operations in the US, Great Britain, Spain and Luxembourg.KBC-S specializes in corporate finance, equity research, sales, brokerage and market making. They also provide clients with growth capital, access to their network of contacts and their equity capital market expertise, M&A and advisory services.

Boards & Committees
Member, Nominating Committee
Current

Fagron NV engages in the development, marketing, and distribution of healthcare products and services. It operates through the following segments: Fagron Specialty Pharma Services (FSPS); Fagron Trademarks (FTM); Fagron Essentials (FE); and HL Technology. The FSPS segment refers to all personalized medication that is prepared in sterile and non-sterile compounding facilities in Europe, the United States, Colombia and South Africa. The FTM segment encompasses the innovative concepts, vehicles and formulations developed by Fagron, often in close cooperation with prescribers, pharmacies and universities. The FE segment relates to all pharmaceutical raw materials, equipment and supplies a pharmacist needs to prepare medication in its own pharmacy. The HL Technology segment is responsible for the development and production of precision components and orthopedic tools for the dental and medical industry. The company was founded in 1990 and is headquartered in Nazareth, Belgium.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Koen Hoffman. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Koen Hoffman's profile does not indicate a business or promotional relationship of any kind between RelSci and Koen Hoffman.